Our medical weight loss program uses compounded Semaglutide and Tirzepatide — the same GLP-1 receptor agonists that have revolutionized weight management. Under clinical supervision, our team provides monitored dosing, regular check-ins, and a comprehensive approach to sustainable weight loss. This is not a mail-order subscription — it is clinically guided medicine with regular evaluation and monitoring.
Our program includes initial metabolic assessment (HbA1c, fasting insulin, lipids, thyroid, metabolic panel), customized dosing protocols, and ongoing monitoring. We use compounded formulations of Semaglutide and Tirzepatide — not brand-name Wegovy — making this therapy more accessible while maintaining pharmaceutical quality. Combined with nutrition guidance and optional peptide support, our program delivers sustainable, medically supervised weight loss. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2 (MEN2), active pancreatitis, severe GI disease, and pregnancy. Patients on sulfonylureas or insulin require careful monitoring for hypoglycemia.
Key Benefits
Common questions
Frequently asked
What are GLP-1 medications?
GLP-1 receptor agonists (Semaglutide, Tirzepatide) regulate appetite and blood sugar, producing significant sustained weight loss.
What kind of weight loss can I expect?
Most patients lose 15–20% of body weight over 12 months.